Acceptability & Safety of Thermal Ablation in VIA Positive Women to Prevent Cervical Cancer
Authors/Creators
- 1. Assistant Professor, Department of Obstetrics & Gynaecology, SRVS Medical College, Shivpuri, M.P.
- 2. Assistant Professor, Department of Surgery, SRVS Medical College, Shivpuri, M.P.
- 3. Associate Professor, Department of Surgery, SRVS Medical College, Shivpuri, M.P.
Description
Cervical cancer is a significant contributor to the incidence and mortality of cancer in women globally, ranking fourth worldwide. However, the establishment of screening programs has led to a significant decrease in cervical cancer rates. Thermal ablation, a novel ablative procedure for precancerous cervical lesions (CIN), also known as cold coagulation or thermocoagulation, aims to reduce the incidence of cervical cancer. This study evaluated the safety and acceptability of thermal ablation as a treatment for precancerous cervical lesions in women who tested positive on visual inspection with acetic acid (VIA) and Lugol’s iodine (VILI). The study enrolled 50 VIA/VILI positive women, who underwent visual evaluation and thermal ablation therapy at a tertiary care hospital’s Department of Obstetrics and Gynecology. Interviews were conducted after treatment and 4-6 weeks later to assess the participants’ experiences with anxiety, discomfort, and pain during thermal ablation. The results showed that thermal ablation is a safe and widely accepted procedure among women. 90% of the patients did not experience any pain during the treatment, while 10% reported high pain. The most common mild side effect was vaginal watery discharge, and none of the participants experienced any severe adverse effects requiring hospitalization or urgent care. Additionally, 62% of the women were willing to repeat the procedure if necessary. These findings suggest that thermal ablation is a safe and minor surgical procedure that can improve screening and treatment in a single visit, thus optimizing cervical cancer control, particularly in low-resource settings. As a result, thermal ablation has the potential to be a valuable supplement to current cervical cancer screening and treatment options.
Abstract (English)
Cervical cancer is a significant contributor to the incidence and mortality of cancer in women globally, ranking fourth worldwide. However, the establishment of screening programs has led to a significant decrease in cervical cancer rates. Thermal ablation, a novel ablative procedure for precancerous cervical lesions (CIN), also known as cold coagulation or thermocoagulation, aims to reduce the incidence of cervical cancer. This study evaluated the safety and acceptability of thermal ablation as a treatment for precancerous cervical lesions in women who tested positive on visual inspection with acetic acid (VIA) and Lugol’s iodine (VILI). The study enrolled 50 VIA/VILI positive women, who underwent visual evaluation and thermal ablation therapy at a tertiary care hospital’s Department of Obstetrics and Gynecology. Interviews were conducted after treatment and 4-6 weeks later to assess the participants’ experiences with anxiety, discomfort, and pain during thermal ablation. The results showed that thermal ablation is a safe and widely accepted procedure among women. 90% of the patients did not experience any pain during the treatment, while 10% reported high pain. The most common mild side effect was vaginal watery discharge, and none of the participants experienced any severe adverse effects requiring hospitalization or urgent care. Additionally, 62% of the women were willing to repeat the procedure if necessary. These findings suggest that thermal ablation is a safe and minor surgical procedure that can improve screening and treatment in a single visit, thus optimizing cervical cancer control, particularly in low-resource settings. As a result, thermal ablation has the potential to be a valuable supplement to current cervical cancer screening and treatment options.
Files
IJPCR,Vol15,Issue5,Article58.pdf
Files
(323.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:8a3267aa8c048a9ccaeed64414d3d8d7
|
323.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-04-30
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue5,Article58.pdf
- Development Status
- Active
References
- 1. IARC/WHO. GLOBOCAN 2019: Estimated cancer incidence, mortality and prevalence worldwide in 2019. Cervical Cancer Fact Sheet. Available at: https://gco.iarc.fr/today/data/factsheets /cancers/23-Cervix-Uteri-fact-sheet.pdf. 2. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019;20(3):394–407. 3. Arbyn M, Weiderpass E, Bruni L, et al: Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health. 2020; 8: e191-e203. 4. WHO guidelines – use of cryotherapy for cervical intraepithelial neoplasia. Geneva: World Health Organization; 2011 (http://www .who.int/reproductivehealth/publications /cancers/9789241502856/en/, accessed 20 June 2019). 5. WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization. Geneva: World Health Organization, 2014 (https://www.who.int/reproductivehealth /publications/cancers/treatment_CIN_2- 3/en/, accessed 20 June 2022). [Reference list] 6. World Health Organization: A Global Strategy for elimination of cervical cancer. https://www.who.int/activities/aglobal-strategy-for-elimination-ofcervicalcancer 7. World Health Organization: WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. https://www.who.int/reproductivehealth/ publications/ thermal-ablation-forcervical-pre-cancer-lesions/en/. 8. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Geneva: World Health Organization; 2019. Executive summary. Available from: https://www.ncbi.nlm.nih.gov/books/NB K549186/ 9. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Geneva: World Health Organization; 2019. 1, Introduction. Available from: https://www.ncbi.nlm.nih.gov/books/NB K549179/ 10. Pinder LF, Parham GP, Basu P, Muwonge R, Lucas E, Nyambe N, et al. Thermal ablation versus cryotherapy or loop excision to treat women positive forcervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial. Lancet Oncol. 2020;21(1):175-84. 11. Mungo C, Osongo CO, Ambaka J, et al. Safety and acceptability of thermal ablation for treatment of human papillomavirus among women living with HIV in Western Kenya. JCO Glob Oncol. 2020; 6:1024–33. 12. Viviano M, Kenfack B, Catarino R, Tincho E, Temogne L, Benski AC, et al. Feasibility of thermocoagulation in a screen-and-treat approach for the treatment of cervical precancerous lesions in sub-Saharan Africa. BMC Womens Health. 2017;17(1):2. 13. Dolman L, Sauvaget C, Muwonge R, Sankaranarayanan R. Meta-analysis of the efficacy of cold coagulation as a treatment method for cervical intraepithelial neoplasia: a systematic review. BJOG. 2014;121(8):929-42. 14. Levy J, de Preux M, Kenfack B, Sormani J, Catarino R, Tincho EF, et al. Implementing the 3T-approach for cervical cancer screening in Cameroon: preliminary results on program performance. Cancer Med. 2020;9(19):7293-300. 15. Banerjee D, Mandal R, Mandal A, Ghosh I, Mittal S, Muwonge R, et al. A prospective randomized trial to compare safety, acceptability and efficacy of thermal ablation and cryotherapy in a screen and treat setting. Asian Pac J Cancer Prev. 2020;21(5):1391-8. 16. Cubaka VK, Schriver M, Cotton P, Nyirazinyoye L, Kallestrup P. Providers' perceptions of communication with patients in primary healthcare in Rwanda. PLOS ONE. 2018;13(4):e0195269. 17. Campbell C, Kafwafwa S, Brown H, Walker G, Madetsa B, Deeny M, et al. Use of thermo-coagulation as an alternative treatment modality in a screen-and-treat programme of cervical screening in rural Malawi. Int J Cancer. 2016;139(4):908-15.